Literature DB >> 31002275

Association of Echocardiographic Parameters of Right Ventricular Remodeling and Myocardial Performance With Modified Task Force Criteria in Adolescents With Arrhythmogenic Right Ventricular Cardiomyopathy.

Guido E Pieles1,2, Lars Grosse-Wortmann1,3,4, Majeda Hader1, Meena Fatah1, Paweena Chungsomprasong1, Cameron Slorach1, Wei Hui1, Chun-Po Steve Fan1, Cedric Manlhiot1, Luc Mertens1, Robert Hamilton1, Mark K Friedberg1.   

Abstract

BACKGROUND: The usefulness of echocardiographic indices, including those already used by modified Task Force Criteria (mTFC), and others such as strain imaging, to identify arrhythmogenic right ventricular cardiomyopathy (ARVC) in adolescence is not well established.
METHODS: Echocardiograms from 120 adolescents investigated for ARVC (13±4 years) were retrospectively analyzed. According to the mTFC, patients were classified into definite (n=38), borderline (n=39), or possible (n=43) ARVC. Results were compared with 35 healthy controls. mTFC echocardiographic parameters were analyzed, as well as comprehensive right ventricular (RV) and left ventricular assessment of function including parameters not included in mTFC such as pulsed-wave tissue Doppler and RV 2-dimensional speckle strain.
RESULTS: mTFC parameters indexed for body surface area were significantly more abnormal in patients with possible, borderline, or definite ARVC compared with controls for parasternal long-axis view of the RV outflow tract. RV end-diastolic diameters were significantly larger in patients versus controls, a difference that increased with likelihood of ARVC. Left ventricular ejection fraction, tricuspid annular peak systolic excursion, and systolic and diastolic pulsed-wave tissue Doppler imaging indices were similar to controls for all groups. Average and segmental RV peak longitudinal systolic strain was significantly lower in patients with definite ARVC (-21±4%) and disease subgroups versus controls (-25±3%). Multivariable risk analysis showed that reduced RV strain was significantly associated with ARVC diagnosis and its likelihood (multivariable odds ratio [95% CI]=1.23 [1.1-1.37]; P<0.001) as was increased end-diastolic diameter at the apical third of the RV (multivariable odds ratio [95% CI]=1.51 [1.33-1.72]; P<0.001).
CONCLUSIONS: mTFC echocardiographic criteria are significantly different between patients and controls and between the different diagnostic groups. However, in our cohort, current echocardiographic mTFC are not met by the majority of adolescent ARVC patients, particularly when indexed to body surface area. Measurement of RV apical dimensions and strain may increase the diagnostic yield of echocardiography for ARVC.

Entities:  

Keywords:  adolescents; cardiomyopathy; diastole; echocardiography; systole

Mesh:

Year:  2019        PMID: 31002275     DOI: 10.1161/CIRCIMAGING.118.007693

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  9 in total

1.  Clinical and genetic features of arrhythmogenic cardiomyopathy: diagnosis, management and the heart failure perspective.

Authors:  Matteo Castrichini; Ramone Eldemire; Daniel W Groves; Matthew Rg Taylor; Shelley Miyamoto; Luisa Mestroni
Journal:  Prog Pediatr Cardiol       Date:  2021-11-02

2.  Combined Use of Voltage Mapping and Speckle-tracking Analysis for the Characterization of Arrhythmogenic Right Ventricular Cardiomyopathy: A Case Report.

Authors:  Amato Santoro; Nicolò Sisti; Claudia Baiocchi; Giulia Elena Mandoli; Antonio Biancofiore; Simone Pistoresi; Valerio Zacà; Salvatore Francesco Carbone; Marta Focardi; Flavio D'Ascenzi; Matteo Cameli
Journal:  J Innov Card Rhythm Manag       Date:  2022-05-15

Review 3.  The adolescent athlete's heart; A miniature adult or grown-up child?

Authors:  Guido E Pieles; A Graham Stuart
Journal:  Clin Cardiol       Date:  2020-07-09       Impact factor: 2.882

4.  Investigating the Accuracy of Quantitative Echocardiographic-Modified Task Force Criteria for Arrhythmogenic Ventricular Cardiomyopathy in Adolescent Male Elite Athletes.

Authors:  Chetanya Sharma; Dan M Dorobantu; Diane Ryding; Dave Perry; Steven R McNally; A Graham Stuart; Craig A Williams; Guido E Pieles
Journal:  Pediatr Cardiol       Date:  2021-10-23       Impact factor: 1.655

5.  Association between genetic variants in the HIF1A-VEGF pathway and left ventricular regional myocardial deformation in patients with hypertrophic cardiomyopathy.

Authors:  Guido E Pieles; Jaime Alkon; Cedric Manlhiot; Chun-Po Steve Fan; Caroline Kinnear; Leland N Benson; Seema Mital; Mark K Friedberg
Journal:  Pediatr Res       Date:  2020-05-06       Impact factor: 3.756

Review 6.  The Prognostic Importance of Right Ventricular Longitudinal Strain in Patients with Cardiomyopathies, Connective Tissue Diseases, Coronary Artery Disease, and Congenital Heart Diseases.

Authors:  Marijana Tadic; Johannes Kersten; Nicoleta Nita; Leonhard Schneider; Dominik Buckert; Birgid Gonska; Dominik Scharnbeck; Tilman Dahme; Armin Imhof; Evgeny Belyavskiy; Cesare Cuspidi; Wolfgang Rottbauer
Journal:  Diagnostics (Basel)       Date:  2021-05-26

7.  Right Ventricular Strain Predicts Structural Disease Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Nitin Malik; Sithu Win; Cynthia A James; Shelby Kutty; Monica Mukherjee; Nisha A Gilotra; Crystal Tichnell; Brittney Murray; Julia Agafonova; Harikrishna Tandri; Hugh Calkins; Allison G Hays
Journal:  J Am Heart Assoc       Date:  2020-04-03       Impact factor: 5.501

8.  The influence of training status on right ventricular morphology and segmental strain in elite pre-adolescent soccer players.

Authors:  Viswanath B Unnithan; Alexander Beaumont; Thomas W Rowland; Nicholas Sculthorpe; Keith George; Rachel Lord; David Oxborough
Journal:  Eur J Appl Physiol       Date:  2021-02-22       Impact factor: 3.078

Review 9.  When Should Premature Ventricular Contractions Be Considered as a Red Flag in Children with Cardiomyopathy?

Authors:  Marianna Cicenia; Massimo S Silvetti; Fabrizio Drago
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.